Identification of Novel Gastric Cancer-Associated CNVs by Integrated Analysis of Microarray

Background: Microarray-CGH facilitates analysis of cancer-associated genomic differences between normal and tumor tissues and provides a genome-wide assessment of copy number variations (CNVs) Methods: To identify CNVs and their clinical significance in gastric cancer. Microarray-CGH was performed to identify CNVs with genomic DNA (gDNA) from normal placenta tissue, peripheral blood mononuclear cells (PBMCs), and normal gastric tissue Results: A total of 20 CNVs. including 8 novel CNVs. were identified by Microarray-CGH Among the 20 CNVs. 5 showed an aberration frequency of over 50% In addition. mRNA expression of W72437 (TFIIH), AI968311 (GAGE10), AI352361. and AAI69807 (PTCHI) in normal tissues and AA485362 (GPXI). AI201652, and AI968311 (GAGE 10) in cancer tissues was associated with DNA change As a whole. incidences of oncogene-like. suppressor-like, and innocent CNVs were 13 8%. 13 2%. and 73 0%. respectively (gain 11 4%. loss 11 8%) AA936795 (C19orf61) appeared as an oncogene-like CNV (9/30, 30%). AI352361 (13/30, 43%). and AA281797 (LOC728340, 10/30.33%) appeared as tumor suppressor-related CNVs Conclusions: This study identified gastric cancer-associated and innocent CNVs in gDNA isolated from placenta tissue and PBMC. which are generally used as reference samples in Microarray-CGH These novel CNVs may be used for gastric cancer-specific mine selection in comparative analysis of genomics J Surg. Oncol. 2010, 102.454-461 (C) 2010 Wiley-Liss. Inc.